Pulmonary Hypertension: State of the Art and Therapeutic Opportunities

肺动脉高压：最新技术和治疗机会

• 批准号: 10682118
• 负责人: TERRY L. SHEPPARD
• 金额: $ 1.53万
• 依托单位: KEYSTONE SYMPOSIA
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-04-01 至 2024-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10682118
• 关键词: Address; Aging; Animal Model; Area; Basic Science; Big Data; Biology; Biomedical Engineering; Blood Vessels; Career Choice; Cell physiology; Collaborations; Creativeness; Data Science; Disease; Educational workshop; Fostering; Future; Genes; Genetic; Head; Heart failure; Heterogeneity; Immune; Inflammation; Joints; Knowledge; Leadership; Learning; Light; Lung; Mentors; Metabolism; Methodology; Mitochondria; Modality; Myocardial; Natural regeneration; New Agents; New Mexico; Outcome; Pathology; Pathway interactions; Patients; Penetrance; Process; Progressive Disease; Pulmonary Circulation; Pulmonary Hypertension; Pulmonary Pathology; Quality of life; RNA; Research; Research Personnel; Resistance; Scientific Advances and Accomplishments; Scientist; Seasons; Symbiosis; System; Therapeutic; Therapeutic Intervention; Translations; Trees; Untranslated RNA; Variant; Work; career; clinical practice; design; effective therapy; efficacy evaluation; epigenome; epigenomics; exosome; health disparity; improved; innovation; insight; interest; lung imaging; meetings; microbiome; multidisciplinary; next generation; novel; novel imaging technology; novel strategies; posters; programs; pulmonary arterial hypertension; sex; symposium

ABSTRACT Support is requested for a Keystone Symposia conference entitled Pulmonary Hypertension: State of the Art and Therapeutic Opportunities, organized by Drs. Marlene Rabinovitch and Kurt Stenmark. The conference will be held in Santa Fe, New Mexico from June 25 - 28, 2023. Pulmonary arterial hypertension is a progressive condition in which narrowing and obliteration of blood vessels results in elevated resistance to flow that culminates in heart failure. Current approved therapies improve survival and quality of life but new research approaches that tackle the complexities of pulmonary hypertension will allow us to identify, develop and pursue new agents that reverse disease. Therefore, this conference is designed to showcase the scientific advances in six areas that impact vascular and immune cell function: i) mitochondrial dynamics (ii) epigenomics and integrated omics (iii) aging and sex determinants (iv) genetics and data science (v) bioengineering and regeneration and (vi) inflammation. The conference program will cover the future of gene editing in pulmonary hypertension and heart failure. Speakers were invited with expertise in the above areas of interest, along with those who work on related aspects of pulmonary hypertension, in order to engage both seasoned and young investigators in a way that will catalyze innovative scientific approaches. Additionally, speakers will be challenged to relate their research to others in the field, to establish relationships and bridge gaps that will identify therapeutic possibilities beyond targeting one pathway or molecule. The program will also cover the pitfalls of current animal models and culture systems, in light of the complexities of the disease. There are also two workshops being planned. The first will highlight novel imaging technology in the field. The second is designed around the process of moving basic discovery to the patient. Finally, this conference will be held jointly with the Keystone Symposia meeting on Heart Failure. Attendees will share joint sessions, workshops, poster sessions, and mealtimes.

摘要 请求支持题为“肺动脉高压：最新进展”的Keystone研讨会 和治疗机会，由Marlene Rabinovitch博士和Kurt Stenmark博士组织。这次会议 将于2023年6月25日至28日在新墨西哥州圣达菲举行。 肺动脉高压是一种进行性的血管狭窄和闭塞状态。 导致血流阻力升高，最终导致心力衰竭。目前批准的治疗方法有所改善 生存和生活质量，但处理复杂的肺动脉高压的新研究方法 将使我们能够识别、开发和追求逆转疾病的新药物。因此，这次会议是 旨在展示影响血管和免疫细胞功能的六个领域的科学进步：i) 线粒体动力学(二)表观基因组学和整合组学(三)衰老和性别决定因素(四)遗传学和 数据科学(V)生物工程和再生以及(Vi)炎症。会议日程将包括 基因编辑在肺动脉高压和心力衰竭中的未来。演讲者被邀请具有以下方面的专业知识 上述感兴趣的领域，以及那些从事肺动脉高压相关方面工作的人，依次 以一种将催化创新科学方法的方式吸引经验丰富的和年轻的研究人员。 此外，演讲者将面临挑战，将他们的研究与该领域的其他人联系起来，建立关系 并弥合差距，将确定治疗的可能性，而不仅仅是针对一种途径或分子。这个 该计划还将涵盖当前动物模型和培养系统的陷阱，鉴于 这种疾病。此外，还计划举办两个讲习班。第一个主题将重点介绍 田野。第二个是围绕着将基本发现转移到患者身上的过程而设计的。最后，这一点 会议将与关于心力衰竭的Keystone研讨会会议一起举行。与会者将共享联合 会议、研讨会、海报会议和用餐时间。